Company Analysis Enveric Biosciences, Inc.
1. Summary
Advantages
- The stock's return over the last year (228.8%) is higher than the sector average (-2.93%).
- Current debt level 2.08% is below 100% and has decreased over 5 years from 119.14%.
Disadvantages
- Price (4.11 $) is higher than fair price (3.16 $)
- Dividends (0%) are below the sector average (0.5317%).
- The company's current efficiency (ROE=-539.57%) is lower than the sector average (ROE=106.63%)
Similar companies
2. Share price and performance
2.1. Share price
2.3. Market efficiency
| Enveric Biosciences, Inc. | Healthcare | Index | |
|---|---|---|---|
| 7 days | -11.4% | -14.5% | 1% |
| 90 days | 554.5% | -5.6% | 2.3% |
| 1 year | 228.8% | -2.9% | 20.4% |
ENVB vs Sector: Enveric Biosciences, Inc. has outperformed the "Healthcare" sector by 231.73% over the past year.
ENVB vs Market: Enveric Biosciences, Inc. has outperformed the market by 208.38% over the past year.
Highly volatile price: ENVB is significantly more volatile than the rest of the market on "NASDAQ" over the last 3 months, with typical deviations of more than +/- 15% per week.
Long period: ENVB with weekly volatility of 4.4% over the past year.
3. Summary of the report
5. Fundamental Analysis
5.1. Stock price and price forecast
Above fair price: The current price (4.11 $) is higher than the fair price (3.16 $).
Price is higher than fair: The current price (4.11 $) is 23.1% higher than the fair price.
5.2. P/E
P/E vs Sector: The company's P/E (-0.0578) is lower than that of the sector as a whole (33.49).
P/E vs Market: The company's P/E (-0.0578) is higher than that of the market as a whole (-68.72).
5.3. P/BV
P/BV vs Sector: The company's P/BV (1.55) is lower than that of the sector as a whole (260.15).
P/BV vs Market: The company's P/BV (1.55) is lower than that of the market as a whole (51.39).
5.3.1 P/BV Similar companies
5.5. P/S
P/S vs Sector: The company's P/S indicator (0) is lower than that of the sector as a whole (129.83).
P/S vs Market: The company's P/S indicator (0) is lower than that of the market as a whole (148.63).
5.5.1 P/S Similar companies
5.5. EV/Ebitda
EV/Ebitda vs Sector: The company's EV/Ebitda (-0.024) is higher than that of the sector as a whole (-28.84).
EV/Ebitda vs Market: The company's EV/Ebitda (-0.024) is higher than that of the market as a whole (-95.22).
6. Profitability
6.1. Profitability and revenue
6.2. Earnings per share - EPS
6.3. Past profitability Net Income
Yield Trend: Negative and has fallen by -16.09% over the last 5 years.
Accelerating profitability: The return for the last year (0%) exceeds the average return for 5 years (-16.09%).
Profitability vs Sector: The return for the last year (0%) exceeds the return for the sector (-598.11%).
6.4. ROE
ROE vs Sector: The company's ROE (-539.57%) is lower than that of the sector as a whole (106.63%).
ROE vs Market: The company's ROE (-539.57%) is lower than that of the market as a whole (-6.23%).
6.6. ROA
ROA vs Sector: The company's ROA (-259.4%) is lower than that of the sector as a whole (-2.32%).
ROA vs Market: The company's ROA (-259.4%) is lower than that of the market as a whole (38.59%).
6.6. ROIC
ROIC vs Sector: The company's ROIC (0%) is lower than that of the sector as a whole (0.8343%).
ROIC vs Market: The company's ROIC (0%) is lower than that of the market as a whole (9.66%).
8. Dividends
8.1. Dividend yield vs Market
Low yield: The dividend yield of the company 0% is below the average for the sector '0.5317%.
8.2. Stability and increase in payments
Unstable dividends: The company's dividend yield 0% has not been consistently paid over the past 7 years, DSI=0.5.
Weak dividend growth: The company's dividend yield 0% has been growing weakly or stagnant over the past 5 years. Growth over only 1 year.
8.3. Payout percentage
Dividend Coverage: Current payments from income (0%) are at an uncomfortable level.
Pay for your subscription
More functionality and data for company and portfolio analysis is available by subscription
Based on sources: porti.ru
